• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

1996 Fiscal Year Final Research Report Summary

An novel hematoporphyrin-anticancer drug conjugate for a therapy of lung metastasis of sarcoma.

Research Project

Project/Area Number 07671566
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Orthopaedic surgery
Research InstitutionAkita University School of Medicine

Principal Investigator

OKADA Kyoji  Akita Univ.Dept.of Orthop.Lecturer, 医学部, 助手 (10185431)

Co-Investigator(Kenkyū-buntansha) SUZUKI Toshio  Akita Univ.Dept.of Pharmaco.Profesor, 医学部, 教授 (20108559)
Project Period (FY) 1995 – 1996
Keywordshematoporphyrin / lung metastasis / porphyrin / sarcoma / Osteosarcoma / metastasis
Research Abstract

1.Implantation of rat osteosarcoma, S-SLM : A appropriate focus of lung metastasis was selected, and implanted into the subcutaneous layr of F344 rat (male). We divided the rats into 5 groups as described below, each group included 10 rats.
2.Preparation of hematoporphyrin-mitomycin C conjugate : Hematoporphyrin and mitomycin c were conjugated by dehydrated reaction under the DCC and 4-dimethylaminopyridine.
3.Experimental group : A single intravenous administration was performed ineach group
1) Control : Only DMSO
2) Low MMC group : 8.97 * 10 -8 mol MMC
3) Low Hp-MMC group : 8.97 * 10 -8 mol Hp-MMC
4) MMC group : 8.97 * 10 -7 mol MMC
5) Hp-MMC group : 8.97 * 10 -7 mol Hp-MMC
4. Results :
1) Survival rate : Low MMC group showed best survival rate 90%). However, survival rate of Low Hp-MMC group, MMC group, Hp-MMC group, were 50%, 20%, and 70%, respectively (p<0.001).
2) Number of metastatic lung nodule : Low MMC group showed lowest lung nodules (average : 35). However, number of nodules of Low Hp-MMC group, MMC group, Hp-MMC group, were 120,35, and 80, respectively.
3) Necrosis ratio of metastatic foci : Low MMC group showed best necrosis ratio (55%). However, necrosis ratio of Low Hp-MMC group, MMC group, Hp-MMC group, were significantly lower, which were 12%, 12%, and 34%, respectively (p<0.001).
5.Conclusion : Hematoporphyrin-mitomycin C conjugate showed a lower anti tumor effect than that of mitomucin C.Side effects of hematoporphyrin-mitomycin C conjugate, however, has been more acceptable. Therefore we believe that hematoporphyrin-mitomycin C conjugate should be a novel anti tumor chemotherapy agent, if a better protocol would be established.

  • Research Products

    (4 results)

All Other

All Publications (4 results)

  • [Publications] Kyoji Okada: "A novel hematoporphyrin-mitomycin C conjugate for lung metastasis of osteoarcoma therapy." Transaction of the 2nd combined meeting of theOrthopaedic research societies of USA,Japan,Canada,& Europe. 451 (1995)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Kyoji Okada: "High-grade surface osteosarcoma of the humerus" Skeletal Radiology. 24. 531-534 (1995)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Kyoji Okada: "A novel hematoporphyrin-mitomycin C conjugate for lung metastasis of osteosarcoma therapy." Transaction of the 2nd combined meeting of the orthopaedic research societies of USA,Japan, Canada, & Europe.451 (1995)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Kyoji Okada: "High-grade surface osteosarcoma of the humerus." Skeletal Radiology. 24. 531-534 (1995)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 1999-03-09  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi